Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors, have improved patient outcomes by targeting specific molecular pathways involved in tumor growth and angiogenesis [5, 6]. This evidence concerns the gene MTOR and neoplasm.